Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.56 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | FABP1 | P07148 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24023148 | 0.86 | NR1H4 (0.59) | NR1H4KAT6AKMT2AALDH1A1MAPT | |
| SCHEMBL22327061 | 0.85 | NR1H4 (0.58) | NR1H4KAT6AKMT2AALDH1A1MAPT | |
| SCHEMBL22327391 | 0.83 | NR1H4 (0.56) | NR1H4KAT6AKMT2AALDH1A1MAPT | |
| SCHEMBL24972999 | 0.79 | KAT6A (0.40) | NR1H4KAT6AKMT2AALDH1A1MAPT | |
| SCHEMBL24002288 | 0.78 | NR1H4 (0.53) | NR1H4KAT6AKMT2AALDH1A1MAPT | |
| SCHEMBL24023340 | 0.77 | ALDH1A1 (0.36) | NR1H4KAT6AKMT2AALDH1A1MAPT | |
| SCHEMBL22219742 | 0.77 | NR1H4 (0.52) | NR1H4KAT6AKMT2AALDH1A1MAPT | |
| SCHEMBL26068742 | 0.77 | GAA (0.42) | NR1H4KAT6AKMT2AALDH1A1MAPT | |
| SCHEMBL22327159 | 0.76 | MAPT (0.55) | NR1H4KAT6AKMT2AALDH1A1MAPT | |
| SCHEMBL26068687 | 0.76 | KAT6A (0.37) | NR1H4KAT6AKMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | NR1H4 3934/4885KAT6A 2123/4885KMT2A 1334/4885 |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | NR1H4 3934/4885KAT6A 2123/4885KMT2A 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.